MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 179 Publications

18 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

  • Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

    IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

     

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 MYXDfZRwfG:6aXOgRZN{[Xl? MWezJO69VQ>? M1zR[lczKGh? MlTsSG1UVw>? MlfPTY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? NV3ySYJ2OjB3N{GwOlk>
A431 Mn7hT4lv[XOnIFHzd4F6 NEPCZYI2KM7:TR?= NFLHNVM2KGh? M1S4bmROW09? MkfCV5VxeHKnc4Pld{B1cGVic3nncoFtcW6pIH;mJGFsfCCjbnSgSZJs MWiyNFU4OTB4OR?=
HepG2 NUKwOlRPS3m2b4TvfIlkKEG|c3H5 NWXjbGVIOTBizszN MmH5NlQhcA>? NHv3PWZFVVOR NFqzVYZU\W6|aYTpfoV{KHKnc3nzeIFvfCClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjJIVn\mWldDDv[kB{d3KjZnXubYI> MWOyNVIxPTl{NR?=
Sk-Hep1 MnjvR5l1d3SxeHnjJGF{e2G7 NFfZT5kyOCEQvF2= MX6yOEBp MY\EUXNQ Mme3V4Vve2m2aYrld{Bz\XOrc4ThcpQh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gd49z[W[nbnni NFPsc2gzOTJyNUmyOS=>
OCUT1 cells harbored PIK3CA (H1047R+/+) M{KyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXGTpo{KM7:TR?= MXu1JIQ> M3\QbmROW09? MVnJR|UxRTBwMUSg{txO M3XFVVIyOjh7Mk[3
K1 cells harbored PIK3CA (E542K+/+) MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\yfXZoOyEQvF2= NUHuSnR5PSCm M3fxUGROW09? MXTJR|UxRTBwNUKg{txO M2r3fVIyOjh7Mk[3
FTC133 cells harbored PTEN (allele deletion and R130+) MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTDTo0yOyEQvF2= MknpOUBl M2\XeWROW09? NILZOoVKSzVyPUCuNVgh|ryP NV7RRmZ{OjF{OEmyOlc>
C643 cells harbored HRAS (G13R+/−) M4jPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HvflMh|ryP NHGze5U2KGR? NYrqN5FLTE2VTx?= NVHEc3RCUUN3ME2wMlI4KM7:TR?= MkX4NlEzQDl{Nke=
Hth7 cells harbored NRAS (Q61R+/−) MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33xV|Mh|ryP M3TPPVUh\A>? M4D3[WROW09? NIm0bpVKSzVyPUSuOUDPxE1? MlH4NlEzQDl{Nke=
TPC1 cells harbored RET/PTC1 rearrangement NHi1[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYThco1vOyEQvF2= NYKyZlVPPSCm NXTMXXYyTE2VTx?= M3zLWWlEPTB;MD61PUDPxE1? MVmyNVI5QTJ4Nx?=
Hth74 M1q1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TnWFMh|ryP M3L0U|Uh\A>? NF3FeGVFVVOR MYjJR|UxRTJwMUmg{txO NWfiSXJ[OjF{OEmyOlc>
KAT18 NH7lXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHHeYRYOyEQvF2= NFzqUZg2KGR? NIXnN|dFVVOR M2XRSWlEPTB;ND62NkDPxE1? M3TUWVIyOjh7Mk[3
SW1736 MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zK[VExOCEQvF2= NXn5N4dSPSCm M{HDS2ROW09? MYfJR|UxRTR5LkW2JO69VQ>? MWWyNVI5QTJ4Nx?=
WRO MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TCeFExODBizszN NFL3TXg2KGR? NVfLZnNSTE2VTx?= NF3L[YpKSzVyPkGwNFAh|ryP NFfkT4IzOTJ6OUK2Oy=>
TAD2 NXrKT25rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofnNVAxOCEQvF2= M4n2[FUh\A>? M{TndmROW09? Mor2TWM2OD5zMECwJO69VQ>? M2H1VVIyOjh7Mk[3
LN229 MojsRZBweHSxc3nzJGF{e2G7 MWKwMlUh|ryP NE\5NJQ3OCCq NGLkO4ZFVVOR Mn35RZVodWWwdIOgZZBweHSxZ3XubYMh\W[oZXP0d{Bw\iCpZX\peIlvcWJ? M2jOfFIzODV5OUG0
T98G M4rYWGFxd3C2b4Ppd{BCe3OjeR?= MXSwMlUh|ryP M4\IW|YxKGh? M{jmSmROW09? MXjBeYdu\W62czDhdI9xfG:pZX7pZ{Bm\m[nY4TzJI9nKGenZnn0bY5q[g>? MnjCNlIxPTd7MUS=
HC11 Mk\SSpVv[3Srb36gRZN{[Xl? NUDiN|FxOTBizszN NX\QOpZyOjRiaB?= NHnvXY1FVVOR MlfkTY5pcWKrdIOg{tIu[2G|ZXnuJIFv\CCDRGLQJJN6dnSqZYPpdy=> NYrhU29POjJ2Mk[2NlE>
MOLT-4 NWPHNHl7S3m2b4TvfIlkKEG|c3H5 NFTJNpYyOCEQvF2= NF3VNno1QCCq MkjnSG1UVw>? NIPHOpNKSzVyPUGuO-KBkc7:TR?= NHrEVZkzOjZzNEK0Ny=>
CEM-R M2\XXmN6fG:2b4jpZ{BCe3OjeR?= M{KyN|ExKM7:TR?= MWG0PEBp MmDSSG1UVw>? MX\JR|UxRTNwM,MAje69VQ>? MVGyNlYyPDJ2Mx?=
CEM-S MWTDfZRwfG:6aXOgRZN{[Xl? NIHVWI0yOCEQvF2= M{m0bVQ5KGh? NWfxdlVzTE2VTx?= NF\abGVKSzVyPUWuNgKBkc7:TR?= Mmn4NlI3OTR{NEO=
MOLT-4 MWrGeY5kfGmxbjDBd5NigQ>? NFTnUYUyOCEQvF2= M4XZdlI1KGh? MVnEUXNQ NUfjcIlbSmyxY3vzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZTDv[kB1cGViY3XscEBkgWOuZR?= NGXIU|EzOjZzNEK0Ny=>
MOLT-4 M3ixd2Z2dmO2aX;uJGF{e2G7 MmOzOQKBkc7:TR?= MmTUOEBp MXfEUXNQ NFPxfmdKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDN2EwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? Ml3BNlI3OTR{NEO=
CEM-R MoGwSpVv[3Srb36gRZN{[Xl? MnTiOQKBkc7:TR?= NEmwbXU1KGh? NFjiXoZFVVOR M4ixRWlv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFO0RU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? MWqyNlYyPDJ2Mx?=
CEM-S M2mwfGZ2dmO2aX;uJGF{e2G7 MVi05qCK|ryP NGLZSIg1KGh? NV75V|hkTE2VTx?= MYXJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFNVGvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> MXmyNlYyPDJ2Mx?=
HepG2 cell NX3BPVROU2mwYYPlJGF{e2G7 M1XvfFIxKM7:TR?= MViyOEBp NEf6enJFVVOR NUDBcVhsTG:5boLl[5Vt[XSnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= M2fTclI{Pzl5M{G5
HepG2 cell M13Kdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLoN|Ah|ryP NUXwWmdKOjRiaB?= M{HjSGROW09? MoXZTY5pcWKrdIOgZ4VtdCCpcn;3eIg> M3XlOVI{Pzl5M{G5
HepG2 cell NEHVe2ZCeG:ydH;zbZMhSXO|YYm= NFTQcnkzOCEQvF2= NVLsTm8zOjRiaB?= MmXaSG1UVw>? M2r0Omlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M2\4XlI{Pzl5M{G5
GEO MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYG1NFAhdk1? MUW3NkBp NInUeHlFVVOR MnrpTY5pcWKrdIOgZ4VtdCCpcn;3eIg> M3X5V|I1PThzMkOx
CNE-1 M2PSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvuWXc5OTBizszN NUTlS3NFQTZiaB?= NWntbZFYTE2VTx?= NYPqXGhmUUN3ME2yMlk3KM7:TR?= MmD6NlU{OzZ7MkW=
CNE-2 Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYixNEDPxE1? M3TOfFk3KGh? M2jDXGROW09? NVHneYVCUUN3ME20MlU{KM7:TR?= NYDne|Q1OjV|M{[5NlU>
HONE-1 M3HJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjlflAyOCEQvF2= MVm5OkBp MlfDSG1UVw>? NXroeohFUUN3ME2zMlM4KM7:TR?= M3rvVVI2OzN4OUK1
SUNE-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKxNEDPxE1? NWraSlFHQTZiaB?= MWnEUXNQ M4fVeGlEPTB;MD61NkDPxE1? M{fwd|I2OzN4OUK1
CNE-2 M2DIWmZ2dmO2aX;uJGF{e2G7 NYPKPYVVOTBizszN NYfmPXJjPDhiaB?= MVLEUXNQ NVz1clVHUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCJMR?= NGHpV4UzPTN|NkmyOS=>
HONE-1 NGXLT4RHfW6ldHnvckBCe3OjeR?= MYSxNEDPxE1? Mn\COFghcA>? NFrpVXFFVVOR MYnJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JGcy M2LiN|I2OzN4OUK1
NEC8 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEm2OVEh|ryP NIrv[nRUSU6JRWK=
P12-ICHIKAWA NXzKeYxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXXUXRQUUN3ME2wMlEyPjJizszN MWrTRW5ITVJ?
MDA-MB-175-VII NH33NmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMUO3N|gh|ryP MlvuV2FPT0WU
AsPC-1 NEjDSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHueXVKSzVyPUCuNlIyOjJizszN NWLTT5JlW0GQR1XS
T47D NWPFWHlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTITWM2OD1yLkK4NlUh|ryP MmrCV2FPT0WU
HH NHzp[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;2TWRVUUN3ME2wMlMxOjh|IN88US=> NFXIe5pUSU6JRWK=
MOLT-16 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDXdHpnUUN3ME2wMlMxOzJizszN NVnZXWVZW0GQR1XS
ES5 NYTEdVBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwM{S0OVUh|ryP MoP5V2FPT0WU
RS4-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TiSGlEPTB;MD6zOFYyKM7:TR?= M4DQW3NCVkeHUh?=
KARPAS-45 NG\zUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwM{ezNlEh|ryP NWXzbmFWW0GQR1XS
NCI-H720 NYPmNGNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PwXWlEPTB;MD6zO|Y4QSEQvF2= MWDTRW5ITVJ?
H9 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1OzPGlEPTB;MD6zPFg5OyEQvF2= MYrTRW5ITVJ?
EFM-19 MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vyNGlEPTB;MD60OFAyKM7:TR?= NWPNbJRNW0GQR1XS
SBC-1 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LCV2lEPTB;MD60OFA{PSEQvF2= MkLRV2FPT0WU
A4-Fuk M4nXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHpTWM2OD1yLkS2PFY5KM7:TR?= NUS4W3BZW0GQR1XS
NCI-H1563 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwNEixPFkh|ryP NVfjbJVXW0GQR1XS
HCC1419 M4j3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XuTmlEPTB;MD60PFg6OiEQvF2= MlPSV2FPT0WU
H-EMC-SS NWrQeGtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvZdXlKSzVyPUCuOFk6OzlizszN NXuxe2ZYW0GQR1XS
BHT-101 NEXkN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwNUK5OlEh|ryP MnnsV2FPT0WU
IGROV-1 NEXk[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIeyc25KSzVyPUCuOVUzPDlizszN MYXTRW5ITVJ?
HGC-27 Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\HVWlEPTB;MD61Olc5OyEQvF2= MonhV2FPT0WU
MDA-MB-361 NUfrelZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jNOmlEPTB;MD61O|c3OSEQvF2= NYKyOFJDW0GQR1XS
KE-37 M3\tXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwNUiyOkDPxE1? M1zsOnNCVkeHUh?=
HCC70 NXTSXHJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrKTWM2OD1yLkW5PFI4KM7:TR?= M1HlSnNCVkeHUh?=
LNCaP-Clone-FGC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPzVlBoUUN3ME2wMlYyODR6IN88US=> NHXaeo5USU6JRWK=
HAL-01 NX:0do5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXHTWM2OD1yLk[yNVMh|ryP NIK4Um9USU6JRWK=
HT MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonSTWM2OD1yLk[zNlM6KM7:TR?= MUjTRW5ITVJ?
MDA-MB-415 NX:ySVNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwNkO2NlYh|ryP MUDTRW5ITVJ?
NOS-1 M2LqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\QdFdyUUN3ME2wMlY{PzJ|IN88US=> NFG2XYpUSU6JRWK=
DU-145 M1\jc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LrTmlEPTB;MD62OFc1PSEQvF2= NHn3TpNUSU6JRWK=
OCUB-M NVTDUY5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PqS2lEPTB;MD63NFk3PiEQvF2= NFjUNXNUSU6JRWK=
VA-ES-BJ NHKzdoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf4epBbUUN3ME2wMlc{ODJ3IN88US=> M1OzN3NCVkeHUh?=
J-RT3-T3-5 NI\RXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTVXnNKSzVyPUCuO|Q1ODNizszN MXvTRW5ITVJ?
MOLT-4 M3XzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\aSGlEPTB;MD64NFU5OiEQvF2= MWnTRW5ITVJ?
NB7 NGXkdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\Db45KSzVyPUCuPFI1OTFizszN MYPTRW5ITVJ?
L-363 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\zTWM2OD1yLkizOFQzKM7:TR?= M3PH[3NCVkeHUh?=
NKM-1 M{P0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PwU2lEPTB;MD64OlI2OyEQvF2= M{DhOXNCVkeHUh?=
HOP-92 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwOEeyNlMh|ryP MXHTRW5ITVJ?
OAW-42 M4jBNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDSeGNlUUN3ME2wMlg5PzJizszN MYHTRW5ITVJ?
HuO9 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3PVoJKSzVyPUCuPVI4PTFizszN M1fpc3NCVkeHUh?=
MFE-280 NU\0S2FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLOVYJVUUN3ME2wMlk3PDZ3IN88US=> NXLlXHoxW0GQR1XS
EM-2 NXnJeJBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\WXVhKSzVyPUCuPVc6OzlizszN MojYV2FPT0WU
NCI-H520 M1r3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LhV2lEPTB;MD65PFU6OiEQvF2= MUjTRW5ITVJ?
LB2241-RCC NXjSfFJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwOUm3N|Qh|ryP NU[zTFFVW0GQR1XS
SK-NEP-1 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC3TWM2OD1zLkG0OFg2KM7:TR?= NFrjdnRUSU6JRWK=
LXF-289 M1jjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwMUexOVYh|ryP NHL1WZpUSU6JRWK=
EPLC-272H M1SzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T6b2lEPTB;MT6xO|I2PiEQvF2= NFHBeY1USU6JRWK=
COLO-684 MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFwMkO3NlUh|ryP MlP5V2FPT0WU
ES1 NVqyVnVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFwMkSwOlUh|ryP M2jE[HNCVkeHUh?=
DOHH-2 NELpe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\x[GlEPTB;MT6yPFIxOyEQvF2= NVnBfYZKW0GQR1XS
CTB-1 NF\wb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH24e5BKSzVyPUGuNlg6QSEQvF2= NGn5UolUSU6JRWK=
G-401 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjUTWM2OD1zLkK5O|k2KM7:TR?= Ml3BV2FPT0WU
LoVo NXXzW5ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLETWM2OD1zLkOyOVM1KM7:TR?= MofuV2FPT0WU
Ramos-2G6-4C10 NF\xbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnnT2N1UUN3ME2xMlM{PzBzIN88US=> NUTHUHV{W0GQR1XS
MFM-223 NH\K[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fqbWlEPTB;MT6zOFQ3OSEQvF2= MWTTRW5ITVJ?
PA-1 M2XLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO1TWM2OD1zLkO1NlY2KM7:TR?= MXvTRW5ITVJ?
697 NVXjW|dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL0TWM2OD1zLkO3OlE3KM7:TR?= MUHTRW5ITVJ?
QIMR-WIL NHntUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1y1dWlEPTB;MT60PVEyPiEQvF2= NH:x[npUSU6JRWK=
HOS NV\weGlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn64TWM2OD1zLkS5OVU5KM7:TR?= MYrTRW5ITVJ?
DMS-273 M1;mcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFwNUG5OVkh|ryP NHLB[2dUSU6JRWK=
ME-180 NXW1SlR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P1RWlEPTB;MT61Olg6OSEQvF2= M{e2d3NCVkeHUh?=
HCC2218 NWnpbGVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDOT45KSzVyPUGuOlgzOjVizszN MmjKV2FPT0WU
CAL-54 Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPPU5UyUUN3ME2xMlcyOjR{IN88US=> MmPZV2FPT0WU
OMC-1 NGTrbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwN{S2O|ch|ryP M3PwUnNCVkeHUh?=
COR-L105 M2Wz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnpTWM2OD1zLke5O|M4KM7:TR?= NIDOVIpUSU6JRWK=
BV-173 M1fxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTKelVNUUN3ME2xMlgyODd2IN88US=> NFTS[lJUSU6JRWK=
RKO M4fBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFwOEexNFEh|ryP MlPpV2FPT0WU
SNU-387 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fpOGlEPTB;MT64PFQxPiEQvF2= NUPRZnAxW0GQR1XS
SW1088 M1TLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED1ZWZKSzVyPUGuPVQ3ODZizszN NHrrb2dUSU6JRWK=
Hs-578-T NY\MXZFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLzTWM2OD1{LkGxOFM{KM7:TR?= MkLsV2FPT0WU
OC-314 NY[4dpRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\Dd5pKSzVyPUKuNVUxQDZizszN MVnTRW5ITVJ?
RMG-I MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;hTWM2OD1{LkG2N|k5KM7:TR?= NX\aTGtPW0GQR1XS
NCI-H1395 NFWwOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX0TWM2OD1{LkG4NFkyKM7:TR?= M1jOXXNCVkeHUh?=
GAMG MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnJPIRKSzVyPUKuNlM5PDVizszN MX7TRW5ITVJ?
LB1047-RCC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrke4NKSzVyPUKuNlQ{OTdizszN NGjncXpUSU6JRWK=
MN-60 M3T0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;EfGlEPTB;Mj6yPVkzOyEQvF2= NI[0TYFUSU6JRWK=
OAW-28 Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Hsd2lEPTB;Mj6yPVk2OSEQvF2= M2e4b3NCVkeHUh?=
NCI-H2228 NWixZ3VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HzbWlEPTB;Mj6zNVU2OiEQvF2= MknwV2FPT0WU
ABC-1 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3ETWM2OD1{LkOzNlU{KM7:TR?= MlTOV2FPT0WU
LS-513 NYPQT4p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PuSGlEPTB;Mj6zN|Q5PCEQvF2= NILvVodUSU6JRWK=
KS-1 M3XFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn3TWM2OD1{LkO4NVkyKM7:TR?= M1nXRXNCVkeHUh?=
NB69 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP6S2tEUUN3ME2yMlM5QTh|IN88US=> NX7UNIVDW0GQR1XS
VM-CUB-1 MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP6TXAxUUN3ME2yMlM6ODh|IN88US=> MXfTRW5ITVJ?
D-423MG MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPMTWM2OD1{LkSxNFQ1KM7:TR?= NUSxTnhRW0GQR1XS
EW-18 NVHCRphzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJwNEG5N|kh|ryP MYfTRW5ITVJ?
YH-13 MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf6cZNuUUN3ME2yMlQ3OTV|IN88US=> MV7TRW5ITVJ?
T-24 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvhTWM2OD1{LkS3PFgyKM7:TR?= MkC1V2FPT0WU
ES8 M3;1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P0RmlEPTB;Mj60PVI5PyEQvF2= NH31OG5USU6JRWK=
ES3 M1zDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwNEm3OVkh|ryP MmK5V2FPT0WU
RXF393 NHHqXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwNkC0PFch|ryP MkHoV2FPT0WU
RPMI-8226 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2i5SGlEPTB;Mj62Nlk2OyEQvF2= MkXnV2FPT0WU
AGS NF21XmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnWbYVxUUN3ME2yMlczOTN5IN88US=> NU\yTY5{W0GQR1XS
HCC1395 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvtWYtKSzVyPUKuO|UyQDdizszN NH;Mc4RUSU6JRWK=
MV-4-11 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L0[2lEPTB;Mj63OVI3PiEQvF2= MX7TRW5ITVJ?
A204 M4LHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjhUpJjUUN3ME2yMlg{QDd{IN88US=> MX;TRW5ITVJ?
MCF7 NIOxV5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXOTWM2OD1{Lki2NVE4KM7:TR?= NYTwO2IzW0GQR1XS
SNU-423 M2rYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJwOEmyOFIh|ryP NYe2[4MzW0GQR1XS
NCI-H1048 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rVNmlEPTB;Mj65Olg3PSEQvF2= NInlZpBUSU6JRWK=
GR-ST M4T0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTNwMES2NVEh|ryP M3\TWnNCVkeHUh?=
EoL-1- MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljMTWM2OD1|LkC3NFU5KM7:TR?= M2jJb3NCVkeHUh?=
HuH-7 MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DhbGlEPTB;Mz6wPVQ3PCEQvF2= NFH1c|NUSU6JRWK=
OS-RC-2 NGDXT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jZcmlEPTB;Mz6xNVE6KM7:TR?= MULTRW5ITVJ?
EW-3 M2Tud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnPUG5KSzVyPUOuNVk2OjlizszN MX;TRW5ITVJ?
NCI-H747 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHVemFjUUN3ME2zMlIxPjl2IN88US=> Mmq4V2FPT0WU
EW-16 MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTNwMkG4O|kh|ryP M4nIUnNCVkeHUh?=
DOK MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj6[|Q4UUN3ME2zMlIzQDV7IN88US=> M4DibXNCVkeHUh?=
HCC2157 NXzHW4lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X3RWlEPTB;Mz6zPFE4QSEQvF2= M1zqW3NCVkeHUh?=
OVCAR-3 NV;ie4ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XMfGlEPTB;Mz60NFc5PiEQvF2= MY\TRW5ITVJ?
NCI-H1623 MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTLOJBxUUN3ME2zMlQyOjJ2IN88US=> MV3TRW5ITVJ?
H4 NFf4fZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTNwNEW2NlYh|ryP NIjSNlhUSU6JRWK=
SW1710 NUjxVmtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7xXppKSzVyPUOuOFY3PzhizszN MWXTRW5ITVJ?
RT-112 MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVriWog5UUN3ME2zMlUzOzh6IN88US=> NUnkTo1MW0GQR1XS
DMS-114 M3viPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTNwNkKyO|gh|ryP NHHBUohUSU6JRWK=
AN3-CA MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTNwNkK0OVYh|ryP MUXTRW5ITVJ?
KNS-62 Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G3ZWlEPTB;Mz62N|M{QCEQvF2= NVL4N|J3W0GQR1XS
SJRH30 M1Sxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi3TWM2OD1|Lk[5NVIzKM7:TR?= MlvYV2FPT0WU
G-402 Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj4TWM2OD1|LkewO|EyKM7:TR?= MVvTRW5ITVJ?
MHH-PREB-1 NWDJ[pdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTNwN{KwN|gh|ryP NULSO5ZQW0GQR1XS
P30-OHK M2ezRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTHd2lkUUN3ME2zMlgxQTd4IN88US=> NIqwcHJUSU6JRWK=
RVH-421 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HFNWlEPTB;Mz64NVc5QCEQvF2= Mlr6V2FPT0WU
LU-134-A M2rRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XG[GlEPTB;Mz64PFQzQCEQvF2= M3H6PHNCVkeHUh?=
ECC10 Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL0UW1KSzVyPUOuPVM3OjJizszN MkXWV2FPT0WU
TGW NHvJ[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLkVoV4UUN3ME20MlAzOzB3IN88US=> NVvQ[VJ7W0GQR1XS
MLMA NYrQPGNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml63TWM2OD12LkCyPVY3KM7:TR?= Mnq4V2FPT0WU
SCC-25 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnXdpJKSzVyPUSuNFY2PjZizszN NGfSWlZUSU6JRWK=
TYK-nu M2Px[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL2T|M{UUN3ME20MlA6PTN2IN88US=> NEC3OmVUSU6JRWK=
LAMA-84 MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\hbWZRUUN3ME20MlE1OTlzIN88US=> MUPTRW5ITVJ?
Calu-3 M1zDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[1fWlEPTB;ND6yOFQyPiEQvF2= Mn7qV2FPT0WU
NCI-H460 M4HNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTSTWM2OD12LkK2OFQ{KM7:TR?= MnHOV2FPT0WU
EGI-1 NFzuUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn35TWM2OD12LkO3O|c5KM7:TR?= NV\PbVg5W0GQR1XS
NCI-H292 M13Ze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjlTWM2OD12LkO4NVQ3KM7:TR?= NWPXO21TW0GQR1XS
HCE-T NILMNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L6TWlEPTB;ND60NVU4QSEQvF2= MWnTRW5ITVJ?
EW-11 MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPIW5dKSzVyPUSuOFE5OzhizszN MlnSV2FPT0WU
ATN-1 M1;pWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTkcnFbUUN3ME20MlQ1OzB2IN88US=> NHnpWGpUSU6JRWK=
NB5 NWf5Tnk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTRwNUO2PVch|ryP MVPTRW5ITVJ?
KLE NYL0OIMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTXTWM2OD12LkewNVk5KM7:TR?= NH\IOVhUSU6JRWK=
CAL-39 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPYTWM2OD12LkeyNVQ3KM7:TR?= M4fyXHNCVkeHUh?=
TI-73 M{m0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfDe45KSzVyPUSuPFA3ODlizszN NVPnTGluW0GQR1XS
HO-1-N-1 M2XqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HSZmlEPTB;ND65OFIh|ryP NI\seJZUSU6JRWK=
786-0 MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTRwOUS2O|Mh|ryP MYHTRW5ITVJ?
SK-N-DZ MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULSNHNuUUN3ME20Mlk3OTR{IN88US=> MnrRV2FPT0WU
NCI-H446 NIfUN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TGT2lEPTB;NT6yNFAxQSEQvF2= M3H5TnNCVkeHUh?=
ETK-1 NX\UcXhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvnO4dKSzVyPUWuNlEyPjVizszN NVe0cmtIW0GQR1XS
BT-20 M3\zUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHhTW9rUUN3ME21MlIyOzV|IN88US=> MVrTRW5ITVJ?
MEL-HO NFHLepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTVwM{ezN|Yh|ryP NUTHVYZ3W0GQR1XS
CAL-27 NEjtcWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnjTWM2OD13LkS2N|M6KM7:TR?= MYDTRW5ITVJ?
SW872 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTPV|BKSzVyPUWuOVk1OjhizszN M1q4[XNCVkeHUh?=
RPMI-2650 NESwdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTVwNk[xPVkh|ryP NV;ISVg{W0GQR1XS
PFSK-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\qVGlEPTB;NT63Nlc{OiEQvF2= Mli4V2FPT0WU
SF295 M2fP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDVTWM2OD13LkiwOlM{KM7:TR?= MVvTRW5ITVJ?
Becker NYC0OWNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T2VWlEPTB;NT64OlQ4OiEQvF2= NIfpXGJUSU6JRWK=
Saos-2 Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfzWllbUUN3ME21Mlg3PTNizszN NHmxVINUSU6JRWK=
SK-OV-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW4OYxnUUN3ME21Mlk6QDF4IN88US=> NWDW[nFDW0GQR1XS
VMRC-RCZ MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XLXWlEPTB;Nj6wPFc4OyEQvF2= M2TuUXNCVkeHUh?=
EW-22 MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTZwMUm2OFkh|ryP MXjTRW5ITVJ?
BT-474 NVr0N5FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTZwMkOzJO69VQ>? M{DYNHNCVkeHUh?=
BFTC-909 NEe4eZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfNXWZlUUN3ME22MlMxOzR3IN88US=> M3L5UHNCVkeHUh?=
NB12 NIDmdHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHFdWZOUUN3ME22MlM6ODdzIN88US=> MoezV2FPT0WU
D-263MG MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jRN2lEPTB;Nj60OVE3QSEQvF2= M{n1PXNCVkeHUh?=
SNB75 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;EVHVoUUN3ME22MlYxOTR|IN88US=> M1;KdnNCVkeHUh?=
A704 MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTZwNkOwOkDPxE1? NXrOemdQW0GQR1XS
NCI-H1693 NGO5XopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHLb25sUUN3ME22MlY{PjB2IN88US=> Ml3MV2FPT0WU
LN-405 M2XFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\0cVlzUUN3ME22Mlc6Pjd{IN88US=> MnzwV2FPT0WU
CHL-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjUepZVUUN3ME22MlgxODd7IN88US=> NFvrdoFUSU6JRWK=
A498 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTZwOEG5OlEh|ryP MoiyV2FPT0WU
TE-12 NGPBN4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\xZmlEPTB;Nj64N|gyPyEQvF2= NGHpTo5USU6JRWK=
TE-6 NXjmepM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTZwOUOwN|gh|ryP MmLOV2FPT0WU
AU565 M3i0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzJclRKSzVyPU[uPVY6PTdizszN NYHHcIFFW0GQR1XS
RD Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTZwOUiyPFQh|ryP MlnpV2FPT0WU
SW1463 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\YTWM2OD15LkGxNVY5KM7:TR?= MXPTRW5ITVJ?
LU-99A NH7NWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TDVmlEPTB;Nz6xOFMzOiEQvF2= M3r3SHNCVkeHUh?=
NCI-H28 NHXjO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlf2TWM2OD15LkK5NlQh|ryP MWDTRW5ITVJ?
MC-IXC NF3qSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvZeGhNUUN3ME23MlQ5PTd4IN88US=> M1GxVXNCVkeHUh?=
GP5d NUPkd25vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTdwNEi3OlQh|ryP NXzWXZRvW0GQR1XS
GB-1 NGHSUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjyTWM2OD15LkW0PFA1KM7:TR?= NWLuPW9yW0GQR1XS
CAL-33 NEPHPHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTdwNk[yN|Mh|ryP MWHTRW5ITVJ?
MSTO-211H NHvmcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MluzTWM2OD15Lk[3N|M3KM7:TR?= NULwTY9OW0GQR1XS
TE-5 NXfVWI5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHmTWM2OD15Lke5N|M1KM7:TR?= NF3UXnJUSU6JRWK=
D-566MG MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRThwMES0Nlkh|ryP NGTXOJNUSU6JRWK=
JVM-3 Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPWZWFKSzVyPUiuNVUzPjhizszN MnrJV2FPT0WU
T98G Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vHNGlEPTB;OD6xPFA3PyEQvF2= M1vyZ3NCVkeHUh?=
HCC1954 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPDTVZKSzVyPUiuOFUyODRizszN M{\4[nNCVkeHUh?=
SF126 M2nz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH4SnJKSzVyPUiuOFU6OzZizszN NV;LR5NOW0GQR1XS
LB996-RCC M{fqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e2TWlEPTB;OD61N|I2PyEQvF2= MWfTRW5ITVJ?
SKG-IIIa NEXHTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonUTWM2OD16Lk[zNFY6KM7:TR?= NVX4e3lsW0GQR1XS
NCI-SNU-1 NV:yVIt1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NViyd5RSUUN3ME24MlY1PjR|IN88US=> NHLKeFNUSU6JRWK=
LB771-HNC M4flOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRThwNkS2PVYh|ryP MWnTRW5ITVJ?
SCC-4 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTyTWM2OD16Lk[4NlE6KM7:TR?= M2PnNXNCVkeHUh?=
CAMA-1 NHzHOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DLUWlEPTB;OD63O|E1PiEQvF2= MUXTRW5ITVJ?
D-502MG M{\sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfPWlJ1UUN3ME24Mlc5PjJ7IN88US=> NUW2V5hiW0GQR1XS
ESS-1 Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD1SGFKSzVyPUiuPFg4ODRizszN NETmcFNUSU6JRWK=
HEC-1 Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fLVmlEPTB;OD64PVg3PiEQvF2= MlWwV2FPT0WU
NB10 M1rqNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTlwMEKyNlQh|ryP M1OzVnNCVkeHUh?=
8505C NGHPcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTlwMESyN|Ih|ryP M1rLNnNCVkeHUh?=
EFO-27 NHP0PVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXrZ2hTUUN3ME25MlE3PDF{IN88US=> NGjhNFZUSU6JRWK=
HN MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTlwMU[2Nlgh|ryP NHW2WnBUSU6JRWK=
DSH1 NF7SZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfkO5lKSzVyPUmuNlA5PyEQvF2= MVnTRW5ITVJ?
NBsusSR NHHVXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLhTWM2OD17LkK3OFAzKM7:TR?= NVPzUo1VW0GQR1XS
LS-123 NUjVV3NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:2R|FrUUN3ME25MlMyPzZzIN88US=> MU\TRW5ITVJ?
SHP-77 NVzjWpdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\TS2lEPTB;OT6zPVk{PSEQvF2= MYXTRW5ITVJ?
ACN MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlKwTWM2OD17LkWzNlc4KM7:TR?= MV\TRW5ITVJ?
U251 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTlwNkW1OFQh|ryP NXTuTY4yW0GQR1XS
A431 NYTVSG5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7hUZJDUUN3ME25MlgxOjN6IN88US=> MlnHV2FPT0WU
5637 NGC5fHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULXOYV[UUN3ME25Mlg1QTh2IN88US=> MV7TRW5ITVJ?
MDA-MB-157 MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33jR2lEPTB;OT65Nlg4QCEQvF2= NHnnUFhUSU6JRWK=
A101D MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q4SGlEPTB;OT65PVk4PCEQvF2= M2Tad3NCVkeHUh?=
YKG-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLjeJdKSzVyPUGwMlIxODZizszN NFzNN5hUSU6JRWK=
LAN-6 NF63b4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHONnd7UUN3ME2xNE4zOTZ2IN88US=> MYjTRW5ITVJ?
OVCAR-5 MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XZWWlEPTB;MUCuNlQ{OyEQvF2= MnzGV2FPT0WU
A549 M{LrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfFOZNKSzVyPUGwMlM6PzNizszN M2jkXHNCVkeHUh?=
no-11 Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFyLkSzOVMh|ryP MlLrV2FPT0WU
SF539 NXfxfnU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4SyV2lEPTB;MUCuPVA1OSEQvF2= MknYV2FPT0WU
A388 NVv6XHdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnCPJYzUUN3ME2xNU4{QDl5IN88US=> M3rlRnNCVkeHUh?=
DEL NYLEcY9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFzLkSyOEDPxE1? M{jvSHNCVkeHUh?=
SW954 NEfIeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK4TWM2OD1zMT60OlY5KM7:TR?= NUfOWYZEW0GQR1XS
TK10 MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoriTWM2OD1zMT61NlcyKM7:TR?= NULNb2x{W0GQR1XS
SW756 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[1fmlEPTB;MUGuOVI6PCEQvF2= NVPhVnJDW0GQR1XS
PC-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m2[WlEPTB;MUGuOVc3PCEQvF2= NH7DbG9USU6JRWK=
ONS-76 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\nNJFMUUN3ME2xNU43OzZizszN NVTmSldTW0GQR1XS
A427 Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\WNWxKSzVyPUGxMlcxQTNizszN MmHUV2FPT0WU
MEG-01 MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFzLke1NFkh|ryP M2j5PHNCVkeHUh?=
BB30-HNC MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFzLke5PFIh|ryP NHe4WVRUSU6JRWK=
NCI-H1299 M3fFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTFzLkiwPVMh|ryP MX3TRW5ITVJ?
GCT NWXKOGN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TFRmlEPTB;MUGuPFIzQCEQvF2= M2X1OHNCVkeHUh?=
D-247MG MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnvXmJKSzVyPUGxMlk3PjNizszN MWfTRW5ITVJ?
CFPAC-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFzLkm3PFIh|ryP NHrNcIhUSU6JRWK=
EKVX M{O2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF{LkCzNVMh|ryP NFrDU25USU6JRWK=
CAL-51 NUH2c2RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\DR5hKSzVyPUGyMlA4OTZizszN MY\TRW5ITVJ?
BB49-HNC NHfIWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zOXmlEPTB;MUKuNVE4PyEQvF2= Mn;vV2FPT0WU
RPMI-7951 MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF{LkG4OVQh|ryP Mnf3V2FPT0WU
RH-1 M2\SZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjUTJRFUUN3ME2xNk4zOTh2IN88US=> MXfTRW5ITVJ?
BCPAP NHPPbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF{LkS3OFkh|ryP MkLGV2FPT0WU
GCIY NWW0VnEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPwdI14UUN3ME2xNk42OjB7IN88US=> NETa[4dUSU6JRWK=
KNS-81-FD MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHvTWM2OD1zMj61PFY6KM7:TR?= NYLGZ2RXW0GQR1XS
KYSE-140 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C4WGlEPTB;MUKuPFU6PSEQvF2= NVu5XJY{W0GQR1XS
Ca-Ski M37UVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zQdmlEPTB;MUKuPVA1OSEQvF2= M1:4[XNCVkeHUh?=
TGBC1TKB NVrBUowzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1WzW2lEPTB;MUKuPVEyPSEQvF2= MmrmV2FPT0WU
HCC1187 M3f5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW1bHhXUUN3ME2xN{4yQTF{IN88US=> NVLOUo14W0GQR1XS
SJSA-1 M372PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK0SlNKSzVyPUGzMlI{OjdizszN MV7TRW5ITVJ?
CTV-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\2NWlEPTB;MUOuN|Q2KM7:TR?= M4TQ[XNCVkeHUh?=
WM-115 NYHDOllFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzNbm0zUUN3ME2xN{43PDh|IN88US=> MXzTRW5ITVJ?
CHP-212 M13Xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\NS5EzUUN3ME2xN{46PzN7IN88US=> NWHRe4ozW0GQR1XS
SCC-15 M1Lodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj5OVVKSzVyPUGzMlk4PzVizszN NH60dWVUSU6JRWK=
BPH-1 MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF2LkG2OlQh|ryP NXr0V3g2W0GQR1XS
SW780 M1\nPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XLXWlEPTB;MUSuOVAzPSEQvF2= MmjvV2FPT0WU
NCI-H2291 NIDoZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;Gd2lEPTB;MUSuOVg4QCEQvF2= NIr5emFUSU6JRWK=
JEG-3 NYWwe2lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPTTWM2OD1zND62N|I3KM7:TR?= M3\NVnNCVkeHUh?=
CAL-120 M{Xhc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2myfGlEPTB;MUSuO|AzPyEQvF2= NIfOW|dUSU6JRWK=
NCI-H23 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm4NWQxUUN3ME2xOE44QTl5IN88US=> NHnpOmRUSU6JRWK=
MS-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjXfJcxUUN3ME2xOE46PjFzIN88US=> M1rOTnNCVkeHUh?=
PC-14 NVXHZmNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW0em9KSzVyPUG0Mlk3PTRizszN MUTTRW5ITVJ?
D-283MED MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXHOYZ2UUN3ME2xOU4xOTFzIN88US=> MUTTRW5ITVJ?
OE19 NFL1eIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSzTWM2OD1zNT6xOVQyKM7:TR?= NHW0PYlUSU6JRWK=
CAS-1 NE\DOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF3LkSxPFQh|ryP MX3TRW5ITVJ?
NCI-H727 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\XTWM2OD1zNT60NlIyKM7:TR?= NGPRSZpUSU6JRWK=
SiHa M3O0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DVcGlEPTB;MUWuO|U6PCEQvF2= MU\TRW5ITVJ?
BFTC-905 NWPjfVFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF3Lke2PVQh|ryP M{HrSXNCVkeHUh?=
MDA-MB-453 M2TCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTHfINKSzVyPUG2MlE3PDJizszN NH\hTldUSU6JRWK=
HuP-T3 Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXoTWM2OD1zNj62N|c{KM7:TR?= NFHMO4tUSU6JRWK=
SK-LU-1 MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWe5bphqUUN3ME2xOk43QTV4IN88US=> MmjrV2FPT0WU
Detroit562 NGH0cI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\WTWM2OD1zNj63N|E5KM7:TR?= NXnlXnRWW0GQR1XS
HCC1569 Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fjdGlEPTB;MU[uPFM{PyEQvF2= NELKO4NUSU6JRWK=
SK-MES-1 M1j0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvnTWM2OD1zNj64OFE6KM7:TR?= NV[zWZR7W0GQR1XS
BB65-RCC M{HEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXL[4lnUUN3ME2xO{4xPDd7IN88US=> M4jFZnNCVkeHUh?=
LOXIMVI NGL1epRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHKS41PUUN3ME2xO{4xPzB5IN88US=> MYjTRW5ITVJ?
SW1783 M2n3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF5LkGyPEDPxE1? MnfjV2FPT0WU
NH-12 M2nIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfTTWM2OD1zNz6zN|A{KM7:TR?= MmTIV2FPT0WU
UACC-257 M{DCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rUV2lEPTB;MUeuOVUyOiEQvF2= NHX3U|RUSU6JRWK=
KOSC-2 Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi5TWM2OD1zNz62O|U4KM7:TR?= M1G4TnNCVkeHUh?=
KG-1 NGnJ[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\K[FFoUUN3ME2xO{43QTN5IN88US=> NH\ERVlUSU6JRWK=
M059J MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DiSGlEPTB;MUeuO|A{KM7:TR?= MVvTRW5ITVJ?
MHH-NB-11 NG\xTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rNXGlEPTB;MUeuPVY4OyEQvF2= MmLLV2FPT0WU
EW-1 NXPXWmtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjvW5VKSzVyPUG4MlE{QDJizszN NIn3[YtUSU6JRWK=
CAL-85-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF6LkKzOVch|ryP M1nJO3NCVkeHUh?=
639-V MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn1Zo1oUUN3ME2xPE4{OzV2IN88US=> NUP0VHd4W0GQR1XS
C32 MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnOXmRKSzVyPUG4MlQ4OjdizszN NH\0R|VUSU6JRWK=
KM-H2 NX3nOnVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr5TFNkUUN3ME2xPE42OjN{IN88US=> NWHaVXR7W0GQR1XS
A253 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTRTWM2OD1zOD63Nlg3KM7:TR?= M{TydXNCVkeHUh?=
NCI-N87 NF[y[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ztbmlEPTB;MUiuPVAxQCEQvF2= MW\TRW5ITVJ?
8-MG-BA M4C4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTF7LkC2OFYh|ryP NYnsVXBFW0GQR1XS
GI-ME-N MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3yTWM2OD1zOT6xOVQ3KM7:TR?= Mn3JV2FPT0WU
8305C NXnXe2JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLJ[YNxUUN3ME2xPU4zOjh4IN88US=> Mn\ZV2FPT0WU
TE-8 Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPKR5ZbUUN3ME2xPU4{ODJ2IN88US=> NFnXZldUSU6JRWK=
KYSE-270 M4OzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJyLkCyNVch|ryP NH3BOJhUSU6JRWK=
HL-60 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT3TWM2OD1{MD6wPVQyKM7:TR?= NUntNZpiW0GQR1XS
Mo-T NVnJZXBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M323eGlEPTB;MkCuNVY3PSEQvF2= NH\zWmZUSU6JRWK=
NCI-H1355 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK1dFNuUUN3ME2yNE4{Ozd2IN88US=> Mlm0V2FPT0WU
HT-1080 M4\ZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJyLkW0PVch|ryP MnTUV2FPT0WU
MIA-PaCa-2 MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SwU2lEPTB;MkCuOlg5OyEQvF2= NGXBTZRUSU6JRWK=
NCI-H441 NEL6fZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2roRWlEPTB;MkCuO|M4QSEQvF2= MVLTRW5ITVJ?
LCLC-97TM1 NWTLeWFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLBSXhNUUN3ME2yNE45OTN2IN88US=> MYjTRW5ITVJ?
HT-3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojZTWM2OD1{MT61OlMyKM7:TR?= NHS5WnFUSU6JRWK=
22RV1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LudWlEPTB;MkGuOVY5PSEQvF2= M4PScnNCVkeHUh?=
LK-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjyTWM2OD1{MT61PVU{KM7:TR?= NV76elEyW0GQR1XS
CW-2 M1HHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjHXY86UUN3ME2yNU43ODZ7IN88US=> MnnRV2FPT0WU
KYSE-510 M4H6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvFWGVKSzVyPUKxMlYxQTVizszN MkXXV2FPT0WU
CGTH-W-1 Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjF[FlKSzVyPUKxMlcyPjZizszN M{PEVnNCVkeHUh?=
NCI-H661 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJ{LkCzOEDPxE1? MXLTRW5ITVJ?
KU-19-19 MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Dqd2lEPTB;MkKuNVY6PyEQvF2= NIHVT4NUSU6JRWK=
NCI-H2122 NH22S25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLRXpdKSzVyPUKyMlI1OzJizszN M2foTnNCVkeHUh?=
NCI-H526 M2DXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ribWlEPTB;MkKuN|g6PSEQvF2= M3T4THNCVkeHUh?=
NCI-H1650 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjQVI1KSzVyPUKyMlc3PCEQvF2= NX7BcXVCW0GQR1XS
AM-38 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfNPWdKSzVyPUKyMlg3QDlizszN M3PPZXNCVkeHUh?=
NCI-H2405 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELoeHFKSzVyPUKzMlI2OzNizszN M4rtbHNCVkeHUh?=
M14 MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfLTWM2OD1{Mz60NFg5KM7:TR?= M1jPbHNCVkeHUh?=
ES4 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf0eJdXUUN3ME2yN{41OjN{IN88US=> M3Xmb3NCVkeHUh?=
DJM-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES2XWZKSzVyPUKzMlUzOzRizszN NWH0UnF5W0GQR1XS
S-117 M4nGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfPTWM2OD1{Mz63OlUyKM7:TR?= NV20O3djW0GQR1XS
MZ2-MEL MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfqTWM2OD1{Mz63O|U6KM7:TR?= NVTpW2oyW0GQR1XS
SK-MEL-2 NXPqbFZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHhTWM2OD1{Mz64NVM{KM7:TR?= MoPCV2FPT0WU
HCC1806 M4Xr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJ|Lki3NFkh|ryP NYjBSHUxW0GQR1XS
NMC-G1 MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJ2LkKyNlYh|ryP Ml\mV2FPT0WU
DK-MG MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPHTWM2OD1{ND6yPVQh|ryP MmHDV2FPT0WU
SK-N-FI NFq5RlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnLTWM2OD1{ND6zN|AzKM7:TR?= NIPHcplUSU6JRWK=
KINGS-1 NXrRW4Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDLU5BKSzVyPUK0MlQ5PzRizszN MWLTRW5ITVJ?
HCC2998 NF\ifIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJ2LkS4PFUh|ryP MVPTRW5ITVJ?
ALL-PO NHi2OlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ2Lk[xPUDPxE1? NGDheVRUSU6JRWK=
MPP-89 MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT0THZ7UUN3ME2yOU4xPDV6IN88US=> NVLteYZ2W0GQR1XS
NCI-H2342 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n2c2lEPTB;MkWuNVk2OyEQvF2= MX;TRW5ITVJ?
TE-1 NE\nfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTKTWM2OD1{NT6zOVY{KM7:TR?= MkT6V2FPT0WU
RH-18 M{HOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmeyTWM2OD1{NT61PVE5KM7:TR?= M2mxWHNCVkeHUh?=
HT-1376 NHrMR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\hRnR4UUN3ME2yOU43PDZ3IN88US=> NF3oTYZUSU6JRWK=
U-2-OS MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLhbIFSUUN3ME2yOU43QDh6IN88US=> NWfFb4dKW0GQR1XS
BT-549 NYT2eVV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3pTWM2OD1{NT65NFEyKM7:TR?= MkK0V2FPT0WU
NCI-H1755 NFuwSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\sN4RKSzVyPUK1Mlk6PDVizszN NHnsS5FUSU6JRWK=
EW-13 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJ4LkCyO|Qh|ryP MoOzV2FPT0WU
NB13 Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j6PWlEPTB;Mk[uNFk1QSEQvF2= MX\TRW5ITVJ?
NUGC-3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzHfpVKSzVyPUK2MlIyODNizszN MUXTRW5ITVJ?
GMS-10 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHYTWM2OD1{Nj6yN|U{KM7:TR?= MVLTRW5ITVJ?
CHP-134 NVLONpJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvtTmFuUUN3ME2yOk4{QDZ5IN88US=> MnroV2FPT0WU
SW962 NXP5[VkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1njTmlEPTB;Mk[uOVAzOSEQvF2= NV3FeIZlW0GQR1XS
SNU-449 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXIPFR5UUN3ME2yO{4xQDB|IN88US=> MlryV2FPT0WU
HuP-T4 M1Wxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJ5LkC4O|kh|ryP NE[5RZJUSU6JRWK=
SW948 NUHGZphKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJ5LkGzOFQh|ryP NULCcHF7W0GQR1XS
NCI-H226 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJ5LkS1O|gh|ryP Mm[0V2FPT0WU
SK-PN-DW MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT6TWM2OD1{Nz62NFEzKM7:TR?= MYjTRW5ITVJ?
GI-1 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi0UGNUUUN3ME2yO{44OjFizszN MX;TRW5ITVJ?
CAL-12T MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[5OmlEPTB;MkiuNVEyOiEQvF2= MVLTRW5ITVJ?
YAPC M1XURmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;STWM2OD1{OD6yOVY1KM7:TR?= MUfTRW5ITVJ?
SNU-C2B M{DFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJ6LkK5OlQh|ryP MoGxV2FPT0WU
RCC10RGB NVHpbXVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:3W3lvUUN3ME2yPE42PDF5IN88US=> NH\3ZYlUSU6JRWK=
ES7 MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT6SnVKSzVyPUK5MlE1PjVizszN MUPTRW5ITVJ?
PANC-03-27 Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXITWM2OD1{OT60OFQh|ryP NU\4OVRoW0GQR1XS
ES6 M{PjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DUV2lEPTB;MkmuPFE2PyEQvF2= M{LKUXNCVkeHUh?=
HT-1197 MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\4cm4yUUN3ME2zNE4xPTl6IN88US=> M4HIe3NCVkeHUh?=
ZR-75-30 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SwW2lEPTB;M{CuNlM5OyEQvF2= NYHme|dUW0GQR1XS
DB M3S5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTNyLkS5OFIh|ryP M4P1bXNCVkeHUh?=
OCI-AML2 M3Ph[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HHV2lEPTB;M{GuNFY6KM7:TR?= MWLTRW5ITVJ?
NCI-H2170 NXP1bnN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3U[Ww6UUN3ME2zNU45PTF4IN88US=> NVvVU4ZKW0GQR1XS
IST-MES1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPMTWM2OD1|Mj6yPFk4KM7:TR?= NFnFSY1USU6JRWK=
769-P NXnjOGRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Lob2lEPTB;M{KuN|Y1OSEQvF2= NEH6dXdUSU6JRWK=
COR-L23 NVTYSWdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\zXodpUUN3ME2zNk46ODd|IN88US=> MV3TRW5ITVJ?
SW626 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES3UppKSzVyPUOzMlE4PzZizszN NWDGW25UW0GQR1XS
LU-139 NWfCZnl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W4fWlEPTB;M{OuOlYxPSEQvF2= M3PL[nNCVkeHUh?=
HT-144 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzwXJhKSzVyPUOzMlg3OyEQvF2= MoD2V2FPT0WU
CaR-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTPTWM2OD1|Mz65PFIzKM7:TR?= M1\adXNCVkeHUh?=
OE33 NFG5S3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDUd5l6UUN3ME2zOE4zQDV3IN88US=> NIjHN4NUSU6JRWK=
COLO-800 NV7MT3RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTPTWM2OD1|ND6zOlQ4KM7:TR?= M3HOVnNCVkeHUh?=
NB14 M2XOSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTN2LkS2PFQh|ryP Mo\YV2FPT0WU
KURAMOCHI MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH2S25KSzVyPUO2MlEyQThizszN NXzyT4RoW0GQR1XS
SW48 MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTN4LkK0O|Qh|ryP M3ez[3NCVkeHUh?=
Daoy NI\Fc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLnTWM2OD1|Nj62OVM5KM7:TR?= M1nYbHNCVkeHUh?=
TGBC24TKB M{LpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnnNGkzUUN3ME2zOk43PyEQvF2= NVG2VWJCW0GQR1XS
DU-4475 MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfhXXNKSzVyPUO2MlkxOzNizszN MUXTRW5ITVJ?
SW1417 Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPuN45KSzVyPUO4MlA2PTJizszN M3fyNXNCVkeHUh?=
EFO-21 M2jNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C2XmlEPTB;M{iuPVM1QSEQvF2= M1jQ[nNCVkeHUh?=
MG-63 M1z3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXXTWM2OD1|OT6zOFI1KM7:TR?= NWK4dpp3W0GQR1XS
LC-2-ad MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfzTWM2OD1|OT61OVEzKM7:TR?= MoXFV2FPT0WU
NOMO-1 MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3SUWZCUUN3ME2zPU45Ojd2IN88US=> NWHwbFY2W0GQR1XS
COLO-741 NEG0d2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorqTWM2OD12MD6xN|A1KM7:TR?= NWXhc|hUW0GQR1XS
BxPC-3 NFexbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC3TWM2OD12MD61Olg3KM7:TR?= MXLTRW5ITVJ?
HSC-2 M33HUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTRyLkmxNVMh|ryP MUnTRW5ITVJ?
UMC-11 M2HFXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe4TWM2OD12MT6yOlMh|ryP Mkf1V2FPT0WU
HCC1937 M4nh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn2TWM2OD12Mj63PFQ{KM7:TR?= NUS3eI1mW0GQR1XS
Calu-6 NIPLVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnGTWM2OD12Mz6yN|gzKM7:TR?= MWnTRW5ITVJ?
NCI-H1573 NHvrPIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTR|LkO0O|ch|ryP M3fJOXNCVkeHUh?=
SK-N-AS NWXiSXJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7yb5JKSzVyPUSzMlYxOTlizszN MVvTRW5ITVJ?
PSN1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH4bFE6UUN3ME20OU4zPTR6IN88US=> NG\GbnhUSU6JRWK=
TE-11 MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rVfWlEPTB;NEWuOFg1OiEQvF2= NFPneGtUSU6JRWK=
NCI-H1155 M{\yeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ztZmlEPTB;NEWuPFk3PyEQvF2= NXW5fnZxW0GQR1XS
KM12 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHL1cnBKSzVyPUS1MlkxPzZizszN MXnTRW5ITVJ?
RO82-W-1 NXPEUm41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTR4Lkm4NlIh|ryP NELtSFFUSU6JRWK=
SW1573 Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLPOlhKSzVyPUS3MlM4OzZizszN MWnTRW5ITVJ?
CAKI-1 NHvV[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;1Wpp1UUN3ME20PE4zQDR3IN88US=> M4DSTHNCVkeHUh?=
U-118-MG M2LOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D4XGlEPTB;NEiuN|cxOiEQvF2= NWPIVmFOW0GQR1XS
KYSE-520 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfmTWM2OD12OD60NFE3KM7:TR?= NXfJZ|l5W0GQR1XS
HT55 Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnqcG5KSzVyPUS5MlE1PzRizszN MkDmV2FPT0WU
ChaGo-K-1 Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTR7LkS3PVMh|ryP M3\mXXNCVkeHUh?=
IA-LM NVfocWgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TBTWlEPTB;NUSuOlMzOiEQvF2= NVvZWpZLW0GQR1XS
UACC-62 NFyyTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHoOYs6UUN3ME21OU4yODR4IN88US=> M3TidXNCVkeHUh?=
MKN7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M132SWlEPTB;NU[uNFI5PSEQvF2= NGH3OZRUSU6JRWK=
HPAF-II M3y4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\wTWM2OD13Nj60NFc{KM7:TR?= NHnBeHlUSU6JRWK=
NTERA-S-cl-D1 NYTwRnU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\hTWM2OD13Nz63O|gh|ryP MVfTRW5ITVJ?
FTC-133 NEj5bmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnYeJRKSzVyPUW4MlA6PjlizszN MVPTRW5ITVJ?
MHH-ES-1 NIjySmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1SyemlEPTB;NUiuOFgyPCEQvF2= MnTEV2FPT0WU
JVM-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS2NpFKSzVyPUW4Mlk2ODZizszN NXXNPYs{W0GQR1XS
TCCSUP MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzOTWM2OD13OT61Nlc6KM7:TR?= MmfQV2FPT0WU
COLO-824 M1TlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDyTWM2OD14MD6wO|E6KM7:TR?= NXz0WIFrW0GQR1XS
647-V NXXwRlVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXpdFRKSzVyPU[wMlE{PDdizszN M1Gye3NCVkeHUh?=
HD-MY-Z M1LRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXoZWJKSzVyPU[wMlUzQTRizszN NIDkSnVUSU6JRWK=
LS-411N M4O5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTZzLkO5NFMh|ryP Mn:5V2FPT0WU
NCI-H596 NEX1Z2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z1fWlEPTB;NkKuO|Q6PiEQvF2= MYTTRW5ITVJ?
C-33-A MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn6NYpKSzVyPU[0MlA6PTdizszN MV3TRW5ITVJ?
BHY Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq4ZYhMUUN3ME22OE4yOjR3IN88US=> NXrBOFNPW0GQR1XS
KGN Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX6yU|RRUUN3ME22OE42PTF2IN88US=> NXTWd3hMW0GQR1XS
NCI-H1092 MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe0fJhKSzVyPU[1MlAxQTVizszN M3nreXNCVkeHUh?=
MZ1-PC NGi5[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFWwfI9KSzVyPU[1MlU3PDlizszN MUHTRW5ITVJ?
LB831-BLC NUHK[IJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkW2TWM2OD14NT64OFgyKM7:TR?= M2X2dHNCVkeHUh?=
SW620 NYi2WWN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTZ4LkKwN|kh|ryP MoWwV2FPT0WU
HuO-3N1 MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljQTWM2OD14OD6zNlM5KM7:TR?= NF\FUFJUSU6JRWK=
SK-HEP-1 NIP6O2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTZ7Lkm0PFYh|ryP MorYV2FPT0WU
LCLC-103H NYX1SXY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3WbldKSzVyPUewMlY4ODVizszN MXzTRW5ITVJ?
KYSE-70 NHu4UXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLkTWM2OD15MD63PFM2KM7:TR?= MVTTRW5ITVJ?
Mewo M2Th[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;YbndTUUN3ME23NU42ODVizszN Mn\mV2FPT0WU
COLO-668 NYDIUVhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTQeVJQUUN3ME23NU45PDVzIN88US=> MWPTRW5ITVJ?
NCI-H522 NIHQZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVuwfmFSUUN3ME23Nk4{PDF|IN88US=> NYHJe4FUW0GQR1XS
NCI-H1437 NXHSS2JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLsTWM2OD15ND60NFQ5KM7:TR?= Mkf3V2FPT0WU
U-266 NX3iNplUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT2R5lNUUN3ME23OU41PTF4IN88US=> MVrTRW5ITVJ?
MC116 NWmzR4VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPldXZKSzVyPUe1MlU4ODhizszN M{j6[nNCVkeHUh?=
PANC-10-05 NG[xWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTd5LkSyOFMh|ryP MWHTRW5ITVJ?
KYSE-180 NWrCR4VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Hse2lEPTB;N{euOVQ2PCEQvF2= MX\TRW5ITVJ?
JAR NFzWOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTd7LkC1OFYh|ryP MY\TRW5ITVJ?
CAL-62 NVWxeXNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrtTWM2OD16MD6wPVUh|ryP MlTrV2FPT0WU
A3-KAW MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjCd4xjUUN3ME24NE4zOTV2IN88US=> MUXTRW5ITVJ?
PANC-08-13 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXhTWM2OD16MT6xO|Y5KM7:TR?= M{XxcXNCVkeHUh?=
HSC-3 M{CyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHqcnU3UUN3ME24N{4{ODdzIN88US=> MmTKV2FPT0WU
HTC-C3 M1fqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Kzc2lEPTB;OEOuOFcxOiEQvF2= MWHTRW5ITVJ?
KY821 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jQfWlEPTB;OESuNFg6OiEQvF2= MmT3V2FPT0WU
DoTc2-4510 NFzQPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\Kd3A1UUN3ME24OE4zOTh3IN88US=> NULQcW9{W0GQR1XS
NCI-H1581 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj0b5JjUUN3ME24OU41PjRzIN88US=> NVLCbW5QW0GQR1XS
KARPAS-299 M3XDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PEc2lEPTB;OE[uNVk4PyEQvF2= M1mxbHNCVkeHUh?=
IST-MEL1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELpV|ZKSzVyPUi2Mlg5PzJizszN NFPJT2NUSU6JRWK=
KP-N-YS NHHz[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\iTWM2OD16OT65NFI5KM7:TR?= NIDD[WtUSU6JRWK=
KYSE-410 NHHyPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTlzLkSwOFIh|ryP NIrTRWhUSU6JRWK=
TE-10 NFm4ZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITMNndKSzVyPUmxMlU3OTFizszN MlzvV2FPT0WU
SK-MEL-1 M4jPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnuUIJbUUN3ME25Nk46OTB4IN88US=> M3f1U3NCVkeHUh?=
COLO-792 Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTl3LkK1OlQh|ryP NEHtRnlUSU6JRWK=
SCH MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzoTWM2OD17Nj6zPFc4KM7:TR?= MoPMV2FPT0WU
NCI-H1792 M2\xSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O2d2lEPTB;OU[uPFk6OiEQvF2= MoTHV2FPT0WU
NCI-H2029 NGjJfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\STWM2OD17Nj65OVY3KM7:TR?= NVn2[YtxW0GQR1XS
SW684 M{Pi[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\PTWM2OD17OD62OlU1KM7:TR?= MkC2V2FPT0WU
NCI-H209 M1[3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnoU3BKSzVyPUGwNE4yOjFizszN NFfzVFFUSU6JRWK=
HLE NHPsXYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnIbpdKSzVyPUGwOU4zQDJizszN NHHGRm1USU6JRWK=
GOTO NX62OY06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFyNz63O|ch|ryP NUjyd5hVW0GQR1XS
NCI-H1793 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTFyOT6yPEDPxE1? Mn7yV2FPT0WU
D-392MG NE\LNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Xid2lEPTB;MUG3MlM6QCEQvF2= NIrpPWpUSU6JRWK=
SW1990 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF{MD65OVEh|ryP NHvORnFUSU6JRWK=
ML-2 Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKxTWM2OD1zMkGuOlc3KM7:TR?= M32xN3NCVkeHUh?=
NCI-H2452 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXaeoRRUUN3ME2xNlIvOjFizszN MVfTRW5ITVJ?
SK-MEL-30 M1LmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnPVFN{UUN3ME2xNlMvOjR2IN88US=> NX22dZJsW0GQR1XS
SN12C M1nRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zUdGlEPTB;MUK0MlE4PiEQvF2= MoTlV2FPT0WU
NCI-H1770 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX5TWM2OD1zMkWuOVE1KM7:TR?= NGjxPI5USU6JRWK=
SF268 MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF{Nj6xOVgh|ryP NWTueFQ4W0GQR1XS
BALL-1 M2XBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuyTWM2OD1zMk[uNlMh|ryP MoKxV2FPT0WU
COLO-679 MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXUZY5rUUN3ME2xNlYvPzV|IN88US=> M4DVTnNCVkeHUh?=
A2780 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS2XmFKSzVyPUGyPE46QDhizszN MYfTRW5ITVJ?
NCI-H1651 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSxTWM2OD1zM{GuNlQ{KM7:TR?= MkDOV2FPT0WU
NCI-H2087 NYPVU2JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF|MT60PFMh|ryP NXTUSJI3W0GQR1XS
U-87-MG NVe0eWdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnjTWM2OD1zM{OuOlA1KM7:TR?= MWfTRW5ITVJ?
LB2518-MEL M{jGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF|NT65PVMh|ryP MX;TRW5ITVJ?
HCT-116 NX\I[VA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP6SmdKSzVyPUGzO{4zOTdizszN Mnf3V2FPT0WU
Ca9-22 MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zz[GlEPTB;MUO5Mlg{OyEQvF2= NFnZUWlUSU6JRWK=
COR-L88 NUTPSGhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF2Mj6xOEDPxE1? NEfPR5lUSU6JRWK=
CP50-MEL-B NEH0O4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID2SW1KSzVyPUG0OE42ODFizszN M1PyPHNCVkeHUh?=
OVCAR-8 NFPaRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq4cnM1UUN3ME2xOFUvPjN4IN88US=> NUXzW25wW0GQR1XS
SK-MEL-3 NGPKcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33vbWlEPTB;MUS3Mlg4QCEQvF2= MmnKV2FPT0WU
GT3TKB NXjWdFJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnviTWM2OD1zNEmuPVI5KM7:TR?= NHKyRnhUSU6JRWK=
KYSE-450 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1mwT2lEPTB;MUWxMlU{QSEQvF2= NYfzfI02W0GQR1XS
CAPAN-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zxXmlEPTB;MUWzMlA3PCEQvF2= NYniUlZ3W0GQR1XS
BEN MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTQNHFJUUN3ME2xOVMvQTJ6IN88US=> NH;nZWtUSU6JRWK=
NCI-H1304 NYXMdJJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M36zVGlEPTB;MUW0MlY6PCEQvF2= M4i3dnNCVkeHUh?=
KU812 NWrIfJRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LHTWlEPTB;MUW4MlY4PCEQvF2= NXnTPIN3W0GQR1XS
Capan-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHvc5d2UUN3ME2xOlAvPTV|IN88US=> NGW5Z4lUSU6JRWK=
A673 M17CZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfRTWM2OD1zNkGuO|A2KM7:TR?= NEfueYFUSU6JRWK=
SAS M3;hW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\0bHVKSzVyPUG2Nk43PzhizszN M37MTXNCVkeHUh?=
NY M4HUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TwZmlEPTB;MU[1MlMyPCEQvF2= MXLTRW5ITVJ?
HCE-4 M32zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i4fWlEPTB;MU[2Mlg1PSEQvF2= NFHGeGpUSU6JRWK=
MDA-MB-231 M1;3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT2W|ZsUUN3ME2xO|cvPTB|IN88US=> NEfoZYpUSU6JRWK=
no-10 NULUdI04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzYPGZrUUN3ME2xO|gvOTN2IN88US=> NFrvSoVUSU6JRWK=
MZ7-mel MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmflTWM2OD1zN{iuOFY4KM7:TR?= MXHTRW5ITVJ?
NCI-H82 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XIeWlEPTB;MUiwMlE3PSEQvF2= M4fZU3NCVkeHUh?=
CAL-72 NU\UOok2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XtSGlEPTB;MUi1MlA2PCEQvF2= MXPTRW5ITVJ?
NCI-SNU-5 Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvVTWM2OD1zOE[uPFQh|ryP NHTBd3dUSU6JRWK=
OVCAR-4 NHf4U3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknGTWM2OD1zOEiuN|M{KM7:TR?= Mm\wV2FPT0WU
SCC-9 NETEVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDJTWM2OD1zOUGg{txO M{TEVXNCVkeHUh?=
KYSE-150 NGrBS|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjQTWM2OD1zOUGuPFg5KM7:TR?= MX;TRW5ITVJ?
HT-29 M{THWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJyMT6yNVIh|ryP NGWzRphUSU6JRWK=
COLO-678 M3\lSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rZPWlEPTB;MkCxMlQ2KM7:TR?= M1q4[HNCVkeHUh?=
NCI-H650 MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHzOmJKSzVyPUKwNk4yODNizszN NUn4TGVXW0GQR1XS
HuCCT1 NEfFZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJyND6yNFgh|ryP NFvMOXhUSU6JRWK=
SW1116 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW5TWM2OD1{MEeuNFc4KM7:TR?= MUHTRW5ITVJ?
DBTRG-05MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\E[GlEPTB;MkC3MlkxQSEQvF2= NVTXVZJ6W0GQR1XS
SW982 M13TNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJyNz65OFgh|ryP MYfTRW5ITVJ?
RCM-1 M3zCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{myPGlEPTB;MkG0Mlc3OiEQvF2= M3;Yd3NCVkeHUh?=
COLO-320-HSR MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX5NlBMUUN3ME2yNVYvOTJ3IN88US=> MX7TRW5ITVJ?
KNS-42 MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXHTWM2OD1{MU[uOVc1KM7:TR?= MUDTRW5ITVJ?
C2BBe1 M2DhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{POXGlEPTB;MkOxMlkxPSEQvF2= MX\TRW5ITVJ?
CCRF-CEM NIPDZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfGTWM2OD1{NEOuO|k2KM7:TR?= M3TPWXNCVkeHUh?=
SH-4 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrUZW9vUUN3ME2yOFYvODlizszN MlnLV2FPT0WU
LS-1034 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nUVWlEPTB;MkS2MlI3PiEQvF2= M33JRnNCVkeHUh?=
NCI-H2347 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j0[WlEPTB;MkS3MlcyOyEQvF2= NI\WNmdUSU6JRWK=
RPMI-8866 M4rpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvsTWM2OD1{NEmuNlch|ryP MlTJV2FPT0WU
GAK MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rZTGlEPTB;MkWzMlAxOiEQvF2= M{O3UnNCVkeHUh?=
NB6 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS1bFlKSzVyPUK3NE4yKM7:TR?= NIL1VZZUSU6JRWK=
COLO-680N M2D5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4foe2lEPTB;MkeyMlUzPyEQvF2= M2PxWHNCVkeHUh?=
RERF-LC-MS Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXK1dlBHUUN3ME2yO|YvODB5IN88US=> Mnq1V2FPT0WU
TGBC11TKB Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XtSWlEPTB;Mke4MlE4QCEQvF2= NHS4TWFUSU6JRWK=
C8166 M1;FRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJ5OD61NFYh|ryP MlPQV2FPT0WU
HDLM-2 Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jyPGlEPTB;Mkm0MlQxQSEQvF2= M{WyUnNCVkeHUh?=
IGR-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHiTWM2OD1{OUWuOlU6KM7:TR?= NYHCSHV4W0GQR1XS
FADU MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ7Nz61NUDPxE1? MnLQV2FPT0WU
L-428 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn5b4NKSzVyPUK5O{43OTZizszN M4fDRXNCVkeHUh?=
LU-65 MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofYTWM2OD1|MESuN|Ih|ryP M{TxWXNCVkeHUh?=
HEL NHTjUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3STWM2OD1|MEmuPVg{KM7:TR?= NVTN[I9PW0GQR1XS
NCI-H810 NULjdYVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL2TWM2OD1|MUCuOVch|ryP M3OweXNCVkeHUh?=
C3A NFziPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHVVVd5UUN3ME2zNVEvQDB{IN88US=> MUXTRW5ITVJ?
NCI-H630 NYjidlRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi0fmdKSzVyPUOzNk4zQTRizszN NVrTfGVSW0GQR1XS
KP-N-YN NGXPUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDITZJKSzVyPUO0NU4yOjNizszN M2OyVnNCVkeHUh?=
MOLT-13 NWXxWVlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf1dVJKUUN3ME2zOFIvOzJ4IN88US=> NEHSTWhUSU6JRWK=
NCI-H1993 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrSRVhpUUN3ME2zOFIvOzZ3IN88US=> M13FRnNCVkeHUh?=
BE-13 NVHINmtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTN2ND6xOlch|ryP NGjsXZhUSU6JRWK=
IST-SL1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LyTGlEPTB;M{S3MlQxOSEQvF2= MlfsV2FPT0WU
TE-9 M333Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13vNmlEPTB;M{[zMlU5QSEQvF2= NF\nOI1USU6JRWK=
LU-135 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXS[GlRUUN3ME2zOlcvODN3IN88US=> MVLTRW5ITVJ?
T84 MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjmTWM2OD1|N{SuO|EzKM7:TR?= NUXYT|VLW0GQR1XS
K-562 M4L2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTWfmlKSzVyPUO4N{4{PiEQvF2= MmS3V2FPT0WU
SBC-5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHMTWM2OD1|OE[uPVg2KM7:TR?= M1XLXHNCVkeHUh?=
NB17 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fre2lEPTB;M{myMlU6PiEQvF2= NYLUZnNqW0GQR1XS
NCI-H2052 NXj5cHZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1X3fmlEPTB;M{m4MlQ4OiEQvF2= MUDTRW5ITVJ?
HCC38 M4DHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTRyMT61PVMh|ryP NGXp[VlUSU6JRWK=
NCI-H69 NF76OYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknZTWM2OD12NEGuNFg{KM7:TR?= NGTaVm1USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method: MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 15% Captisol 17 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl

CAS No. 1032350-13-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1
NCT01658943 Completed Pancreatic Acinar Cell Carcinoma|Pancreatic Ductal Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage IV Pancreatic Cancer National Cancer Institute (NCI) August 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • Answer:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID